-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On March 8, Euho Pharma, a wholly-owned subsidiary of Biositu, announced an international multi-center (MRCT) Phase I clinical study of its YH002 (OX40 monoclonal antibody) combined with its YH001 (CTLA-4 monoclonal antibody) (No.
This study is an open-label, phase I dose escalation study of YH002 mAb combined with YH001 mAb in patients with advanced solid tumors
Prior to this, Yoho Pharma had completed the single-dose escalation studies of YH001 and YH002, respectively, and the results showed that YH001 and YH002 had good tolerability and safety
About YH002
About YH002YH002 is a recombinant humanized IgG1 monoclonal antibody that specifically targets human tumor necrosis factor receptor superfamily member 4 (TNFRSF4, OX40), thereby inducing pleiotropic downstream anticancer activity
About YH001
About YH001YH001 is an anti-CTLA-4 monoclonal antibody that enhances the body's own immune response against tumor cells by enhancing the removal of regulatory T cells (Treg) in the tumor microenvironment, thereby achieving the purpose of treating various tumors
(Original abridged)